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Abstract It is well established that hormones can cause
cancer, much less known is how they induce this change in
our somatic cells. This review highlights the recent finding
that estrogen can exert its DNA-damaging potential by
directly activating DNA deaminases. This recently discov-
ered class of proteins deaminate cytosine to uracil in DNA,
and are essential enzymes in the immune system. The
enhanced production of a given DNA deaminase, induced
by estrogen, can lead not only to a more active immune
response, but also to an increase in mutations and
oncogenic translocations. Identifying the direct molecular
link between estrogen and a mutation event provides us
with new targets for studying and possibly inhibiting the




In 1938, the first cheap synthetic estrogen-like chemical
(diethylstilbestrol) [1] was made available to patients, first
as an experimental drug, then a few years later with FDA
approval. In previous decades, the benefits of estrogen as a
supposed remedy for a variety of diseases provided fertile
ground for subsequent pharmaceutical exploitations. Yet,
even as early as the late 1800s, clinicians observed a link
between hormones and cancer [2, 3] ,a n di n1 9 3 2 ,
controlled laboratory research showed that estrogen can
induce breast cancers [4]. Surprisingly,overthelast75years,
and despite the subsequent tragedy that resulted from the
diethylstilbestrol, the molecular mechanism behind how
estrogen exerts its oncogenic effects remained mostly elusive.
Tests, including the Ames mutagenesis assay, were unable to
show any significant effect of estrogen as a DNA-damaging
agent. This led to the prevailing conclusion that estrogen-
induced cancerthrough its ability toactivate cellproliferation.
More recently, other theories have tried to explain the
oncogenic potential of estrogen, they included: inhibition of
apoptosis, inactivation of DNA repair, and radicals from
oxidativestressormetabolicderivativesofestrogen(ifpresent
at high concentrations) forming DNA adducts (reviewed in
[5–7]). Although each theory addresses a particular aspect of
estrogen’s oncogenic potential, none are fully satisfactory in
explaining how physiological amounts of estrogen can be
oncogenic.
In 2002, we discovered a novel molecular mechanism
that explained how antibody genes were diversified after
antigen encounter during a humoral immune response [8].
Although known to shuttle between the nucleus and the
cytoplasm, activation-induced deaminase (AID) is a pre-
dominantly cytoplasmic enzyme that, upon activation,
enters the nucleus and is targeted to the immunoglobulin
(Ig) locus. The enzyme then deaminates cytosine bases (dC)
to uracil (dU) in single-stranded DNA (Fig. 1A; for reviews
please see [9–11]). The protein itself had been identified a
few years earlier, as an essential gene for antibody
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hypermutation (SHM)), and was named AID [12, 13].
Usually the DNA lesion (either as dU or as a dU:dG
mismatch) is faithfully repaired back to cytosine (Fig. 1B),
but in the Ig locus it leads to DNA mutations and DNA
recombination (Fig. 1C & D). During SHM, single point
mutations are introduced into the DNA of the Ig locus,
which manifest themselves as, and are selected for, amino
acid changes in the antigen-binding site. Targeting the
constant region of the Ig locus with AID during CSR,
allows for homologous DNA regions to recombine and
loop out the intervening sequence, thereby placing a
different constant domain into the active Ig locus. This
change allows for the antibody to obtain a different effector
function (e.g., from a predominantly membrane-bound IgM
to a soluble IgE). The hallmark for both events is a natural
protein-inducing DNA damage that does not lead to DNA
repair, but to DNA alterations in somatic cells.
Although a number of AID’s functions are unique to
antibody diversification, further analysis has shown that our
genome contains a family of DNA deaminases, some of
which are active anti-viral agents—the AID evolutionary
descendant APOBEC3 family of proteins [14–16]. APO-
BEC3G’s DNA deamination activity is known to inhibit
HIV replication, thought to be by inactivating the first-
strand cDNA of the HIV genome during viral replication.
The discovery of DNA deaminases showed for the first
time, that naturally occurring unaltered enzymes could
mutate the DNA of somatic cells. This was in direct
contrast to the dogma that somatic cells should maintain a
stable genome, and made these enzymes obvious candidate
oncogenes. AID’s oncogenicity was demonstrated when
overexpression of AID in transgenic mice caused tumor
formation in different tissues (lung [17], lymphatic [17],
and liver [18]). More recently, it was shown that AID was
required for the c-myc/IgH translocations of Burkitt
lymphomas [19–21]. As shown in Fig. 1E, during this
translocation c-myc’s promoter recombines with the Ig
locus, causing oncogenic expression of the c-myc gene.
Aside from c-myc [22], it has been known that the process
of SHM (or AID) targeting can occur outside the Ig locus
[23, 24], leading to DNA-deaminase-induced mutation in
tumor suppressors or proto-oncogenes [25]. Importantly
though, the oncogenicity and DNA mutability of the DNA
deaminases are not due to a genetic defect in the proteins,
but rather a consequence of their normal (albeit mis-
regulated) function. With the potential to mutate our
genomes on a daily basis, understanding how AID is
regulated will have a direct impact on immunity, immune
pathologies, and cancer.
In our recent publication [26], we were able show that
estrogen could stimulate the production of AID in primary
B cells. Although primary mature B cells are differentiated
and the AID locus may be ‘available’ (in terms of
chromatin status), we did not require any co-stimulatory
signals to detect the estrogen enhancement. We also
confirmed that the increased production in mRNA showed
a concomitant increase in AID protein. Furthermore, we
observed a direct correlation with estrogen treatment, AID
mRNA production and AID function in Ig class switching,
and somatic hypermutation. Interestingly, the most signif-
icant correlation occurred between estrogen treatment and
the number of potentially oncogenic c-myc/Ig transloca-
tions. We also observed this estrogen-induced response
with most of the APOBEC3s, indicating that the response
to hormones is ancient and conserved.
In terms of molecular mechanisms, we were able to
demonstrate that the cellular estrogen receptor (ER) is
bound to the AID promoter after estrogen treatment. This
seems to recruit a transcription activator complex, and
thereby drive the transcription of the AID gene. Interest-
ingly, when we co-stimulated the cells both with estrogen
and through the NFκB pathway, we observed an enhanced
binding of NFκB to the promoter (known to activate AID
mRNA production [27]), and enhanced AID mRNA
production, which was greater than from either stimulus
alone. This may have immune consequences, in that during
an immune reaction, additional stimulatory signals provided
by estrogen would enhance AID production, leading to a
potential hyperactive humoral immune response.
There is a large body of evidence that females can have a
more pronounced immune reaction upon infection, which
has also been observed at the level of Ig production [28,
29]. This gender bias is also seen in immune pathologies
that are dependent on antibodies, such as systemic lupus
erythematosus (SLE) [30, 31], an autoimmune disease that
is ten times more prevalent in women than in men.
Therefore, the ability of estrogen to enhance or even
hyper-activate AID production, could partially explain the
molecular mechanisms of certain autoimmune pathologies,
via AID’s role in antibody maturation.
Although men have estrogen as part of their endocrine
system, the levels are much reduced compared to women. In
terms of overall immune-fitness though, there does not appear
to be a strong bias of men vs. women. Why then, is a
potentially highly oncogenic protein under the control of such
a panpleiotropic hormone? One can only speculate on the
evolutionaryorigins,butaplausiblehypothesisisthatAID(or
its ancestor) was a genome guardian against foreign DNA (as
mentioned in [8, 10, 14]). The enzyme could act on a mobile
DNA element and inactivate it through deamination/
mutation. This is partially substantiated by the following
observations: (1) AID can partially inhibit retroviral infec-
tions [32]; (2) the APOBEC3 proteins predominately act to
inhibit retroviral infections and retroelement mobility [14,
15, 33]; and (3) the Ig gene and its recombination potential
894 J Mol Med (2009) 87:893–897was evolutionary derived from a retroelement [34, 35]—
thereby linking the activity of AID to an invading DNA. As
a genome guardian, it would be advantageous to have
expression during the most vulnerable stage for retroelement
infection of development—the unfertilized oocyte [36].
Already 5 years ago, we were able to show that AID is
expressed in isolated mouse oocytes and embryonic germ
cells [37]. In our current work [26], estrogen was able to
increase AID mRNA in ovarian-derived primary cells by
over 20-fold. This provides good evidence that AID-induced
deamination is not limited to B cells. In line with a more
global response of AID expression due to estrogen, analysis
of cell lines derived from breast, ovarian, placental, and
prostate tissue, also showed that AID was upregulated in
response to estrogen. Analogously, the other DNA deami-
nases (APOBEC3 members) were also activated in various
tissues and cell lines after estrogen treatment.
It is not fully understood how AID, or its evolutionary
descendants, can inactivate foreign DNA. Aside from
Fig. 1 The function and consequence of AID. (A)A I Du s e s
hydrolytic deamination to form uracil in single-stranded DNA, thereby
inducing a twofold lesion in the DNA, an unusual base and a base
mismatch. (B) Normally, various DNA repair pathways repair the
lesion back to cytosine. (C) and (D) At the immunoglobulin locus, the
AID-induced lesion leads to SHM and CSR. (E) AID can induce
oncogenic translocations during CSR, if the c-myc promoter rear-
ranges into the Ig locus rather than another Ig constant region
Fig. 2 Model of how estrogen induces DNA damage. Estrogen enters
the cell and is bound by the ER. The dimeric ER–estrogen complex
enters the nucleus and induces AID expression. This leads to an
increase in mutations and translocations, and potentially cancer
J Mol Med (2009) 87:893–897 895mutating cytosines in mobile elements in our genomes, an
intriguing additional possibility is via deamination of 5-
methyl-cytosine (5meC). 5meCs in the context of CpGs
usually inactivate the mobility of DNA elements [36], but
some elements are resistant to this mark. We have already
demonstrated that AID can deaminate 5meCpG [37], and
recent genetic evidence has linked AID to CpG DNA
demethylation [38]. It is therefore possible that estrogen-
driven mutation of CpGs during oncogenesis may also be
due to aberrant AID expression.
After more than a century, our current model (Fig. 2)
may have brought us a step closer in understanding how
estrogen can directly induce mutations leading to cancer in
higher vertebrates. We suggest that endogenous or exoge-
nous estrogen is absorbed by the target cell. In the
cytoplasm, the dormant estrogen receptor (ER) will bind
to the ligand and dimerizes. These structural alterations
allow the receptor–ligand complex to enter the nucleus and
target estrogen responsive genes. At the promoter of the
DNA deaminase gene AID, the ER–estrogen complex
recruits proteins for mRNA transcription. The enhanced
AID message is then translated into increased amounts of
AID protein. Excessive AID enters the nucleus and begins
to deaminate cytosine bases to uracil. If these DNA lesions
are not repaired, the consequence is mutation and trans-
locations—leading to autoimmunity or oncogenesis. As the
model predicts, the activity of estrogen is not dependent on
cell replication, occurs in cells that are estrogen responsive,
and does not require any a priori genetic mutations for
manifestation.
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